Physician profile
Joshua A Strauss
NPI 1699919597
$739,180.86
in general payments reported to CMS, 2019-2025
76 companies · $195K in 2025
The $195K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $17K · 2021: $104K · 2022: $86K · 2023: $191K · 2024: $145K · 2025: $195K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $280K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $72K · Travel and Lodging: $68K · Honoraria: $56K · Consulting Fee: $38K · Food and Beverage: $16K · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $280,489.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $72,360.00 |
| Travel and Lodging | $68,080.53 |
| Honoraria | $55,550.00 |
| Consulting Fee | $38,266.50 |
| Food and Beverage | $15,962.94 |
| Education | $101.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $200,918.60 | 2019-2025 | Pemazyre, Zynyz, Pemazyre |
| Exelixis INC. | $179,997.09 | 2019-2025 | Cabometyx |
| Pharmacosmos Therapeutics INC. | $125,224.12 | 2021-2025 | Monoferric, Cosela |
| Amgen INC. | $63,923.76 | 2021-2025 | Lumakras, Imdelltra (Amg757), Xgeva |
| Beigene USA, INC. | $60,604.75 | 2022-2025 | Brukinsa |
| Servier Pharmaceuticals LLC | $35,520.59 | 2021-2025 | |
| Beone Medicines USA, INC. | $23,812.06 | 2025 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $6,303.97 | 2021-2025 | Onivyde |
| Genentech USA, INC. | $5,817.28 | 2019-2024 | Tecentriq, Alecensa, Lunsumio |
| Astrazeneca Pharmaceuticals Lp | $5,615.45 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Abbvie INC. | $5,332.80 | 2019-2025 | Venclexta |
| Pfizer INC. | $4,478.79 | 2019-2025 | |
| Kite Pharma, INC. | $4,260.68 | 2020-2025 | Yescarta |
| Genzyme Corporation | $3,710.54 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $2,875.96 | 2020-2024 | Pyrukynd |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Strauss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.